|
|
|||||||
Comparative Study |
We report the results of four cycles of rituximab therapy in eleven patients with chronic warm antibody type autoimmune hemolytic anemia (AIHA) and six patients with chronic idiopathic thrombocytopenia (ITP). The overall response rate was 64% in the AIHA group (3 complete responses and 4 partial responses) and 83% in the ITP group (4 complete responses, 1 partial response). Responses in AIHA patients with underlying lymphoproliferative disorders receiving rituximab with chemotherapy were generally better sustained, whereas responses in ITP were often transient.
This article has been cited by other articles:
![]() |
S. Berentsen Rituximab for the treatment of autoimmune cytopenias Haematologica, December 1, 2007; 92(12): 1589 - 1596. [Full Text] [PDF] |
||||
![]() |
P. Joly, H. Mouquet, J.-C. Roujeau, M. D'Incan, D. Gilbert, S. Jacquot, M.-L. Gougeon, C. Bedane, R. Muller, B. Dreno, et al. A Single Cycle of Rituximab for the Treatment of Severe Pemphigus N. Engl. J. Med., August 9, 2007; 357(6): 545 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Arnold, F. Dentali, M. A. Crowther, R. M. Meyer, R. J. Cook, C. Sigouin, G. A. Fraser, W. Lim, and J. G. Kelton Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura Ann Intern Med, January 2, 2007; 146(1): 25 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Ahmed, Z. Spigelman, L. A. Cavacini, and M. R. Posner Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune Globulin N. Engl. J. Med., October 26, 2006; 355(17): 1772 - 1779. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |